Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?

Bahçecíoğlu, Ömer Faruk; Gök, Selim; Durmuş, Mefküre

doi:10.1136/ejhpharm-2021-002680

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remdesivir is an adenosine analog that targets the RNA-dependent RNA polymerase and blocks viral RNA synthesis [145]. To date, there is limited information regarding the metabolism of remdesivir; however, it is partially metabolized via CYP3A4 (10%) [149]. This activity would result in reduced efficacy if used in combination with AEDs that induce this enzyme.…”

Section: Seizuresmentioning

confidence: 99%

Neurological Complications of COVID-19: Underlying Mechanisms and Management

Shehata

Lord

Grudzinski

et al. 2021

IJMS

View full text Add to dashboard Cite

COVID-19 is a severe respiratory disease caused by the newly identified human coronavirus (HCoV) Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The virus was discovered in December 2019, and in March 2020, the disease was declared a global pandemic by the World Health Organization (WHO) due to a high number of cases. Although SARS-CoV-2 primarily affects the respiratory system, several studies have reported neurological complications in COVID-19 patients. Headache, dizziness, loss of taste and smell, encephalitis, encephalopathy, and cerebrovascular diseases are the most common neurological complications that are associated with COVID-19. In addition, seizures, neuromuscular junctions’ disorders, and Guillain–Barré syndrome were reported as complications of COVID-19, as well as neurodegenerative and demyelinating disorders. However, the management of these conditions remains a challenge. In this review, we discuss the prevalence, pathogenesis, and mechanisms of these neurological sequelae that are secondary to SARS-CoV-2 infection. We aim to update neurologists and healthcare workers on the possible neurological complications associated with COVID-19 and the management of these disease conditions.

show abstract

Section: Seizuresmentioning

confidence: 99%